Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche Launches New SeqCap EZ Reagent Kits to Maximize Customer Convenience

Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Roche announced today the global launch and availability of a new comprehensive suite of SeqCap EZ Reagent kits for application in single or multiplex target enrichment experiments prior to DNA Sequencing.

Designed to maximize customer convenience and streamline the DNA preparation workflow, the new kits provide customers with an all-inclusive reagent solution for use in their target enrichment experiments such as sequencing the whole Exome or large target genomic regions. The new SeqCap EZ Reagent kits are also optimized and validated for use with Roche’s SeqCap EZ Library probe pools including the latest SeqCap EZ Exome, Oncology and Neurology designs launched in October 2012.

“We’re committed to continuously expanding our leading target enrichment portfolio to address evolving customer needs, such as convenience, capture performance and high quality content ,” said Thomas Schinecker, Head of Roche Sequencing Solutions. “This is only the first phase of our expanded target enrichment reagent offerings. A bead kit will be launched in the coming months to further improve our customers’ convenience.”

The multiplexing capabilities of SeqCap EZ Library allow researchers to manage multiple samples per sequencing run enabling high-throughput research laboratories to capitalize on cost-effective and efficient workflow methods for next-generation sequencing.

“The SeqCap EZ Exome enrichment products have enabled us to strike an important balance in our sequencing platform as we can now sequence a large number of samples and achieve sufficient depth of coverage, while keeping our costs down,” said Dr. Aaron Goldman, Director of Genomics Services, Clinical Genomics Centre in Toronto, Canada. “We are excited to see that Roche is adding target enrichment reagents to their kits as this will simplify our workflow and streamline our ordering process.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche’s MabThera SC Receives Approval in Europe
Company has announced that the EC has approved the SC formulation of MabThera® for people with previously untreated chronic lymphocytic leukaemia (CLL).
Friday, June 03, 2016
FDA Grants Roche’s Cancer Immunotherapy Tecentriq Accelerated Approval
Company has announced that the U.S. FDA has granted accelerated approval to Tecentriq® for the treatment of people with a specific type of advanced bladder cancer.
Friday, May 20, 2016
Tensha Therapeutics to be Acquired by Roche
Tensha Therapeutics, a privately-held company based in Cambridge, MA, has announced it will be acquired by Roche.
Tuesday, January 12, 2016
Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
Roche to Acquire Kapa Biosystems
Acquisition to strengthen next-generation sequencing product offerings.
Friday, August 21, 2015
Roche's Investigational Immunotherapy Atezolizumab Shrank Tumours in People with Lung Cancer
Roche will discuss results with the U.S. FDA as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer.
Wednesday, August 19, 2015
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers.
Friday, August 14, 2015
Roche, Garvan Institute Epigenomic Partnership
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
Wednesday, August 20, 2014
FDA Approves Roche’s Advanced Cervical Cancer Chemotherapy
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
Monday, August 18, 2014
Roche to Acquire Seragon Pharmaceuticals
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer.
Wednesday, July 02, 2014
Roche Invests in Stratos Genomics
Investment by Roche will advance Stratos Genomics chemistry for nanopore sequencing.
Friday, June 27, 2014
Roche Recieves FDA Approval for Cervical Cancer Screening HPV Test
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older.
Friday, April 25, 2014
Roche, Oryzon Announce Epigenetics Collaboration
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions.
Monday, April 07, 2014
FDA Recommends Roche's HPV Test as Primary Screening Tool
Test will assess risk of cervical cancer of women 25 years and older.
Thursday, March 13, 2014
Roche and Molecular Partners Enter into Alliance
Partnership will combine novel biologics with Roche drug-conjugate technology to develop new cancer treatments.
Wednesday, December 04, 2013
Scientific News
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!